The Transcription Factor Foxc1 Promotes Osteogenesis by Directly Regulating Runx2 in Response of Intermittent Parathyroid Hormone (1–34) Treatment

Ningjuan Ouyang¹, Hongliang Li², Minjiao Wang², Hongzhou Shen², Jiawen Si²* and Guofang Shen²*

1 Department of Orthodontics, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology, Shanghai, China. 2 Department of Oral and Cranio-maxillofacial Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology, Shanghai, China

Parathyroid hormone (PTH) is crucial for bone remodeling. Intermittent PTH (1–34) administration stimulates osteogenesis and promotes bone formation; however, the possible targets and underlying mechanisms still remain unclear. In this study, functional links between PTH and Foxc1, a transcription factor reported to be predominant in skeletal development and formation, were indicated. We determined the impacts of Foxc1 on in vitro osteogenic differentiation and in vivo bone regeneration under intermittent PTH induction, and further explored its possible targets. We found that the expression level of Foxc1 was upregulated during osteogenic induction by intermittent PTH treatment, and the elevated expression of Foxc1 induced by PTH was inhibited by PTH1R silencing, while rescued by intermittent PTH supplement. By gain- and loss-of-function strategies targeting Foxc1 in MC3T3-E1 cells, we demonstrated that Foxc1 could promote in vitro osteogenic differentiation by intermittent PTH treatment. Moreover, immunofluorescence analysis indicated the nuclear co-localization of Foxc1 with Runx2. Luciferase-reporter and chromatin immunoprecipitation analysis further confirmed that Foxc1 could bind to the P1 promoter region of Runx2 directly, which plays an indispensable part in osteogenic differentiation and bone mineralization. Meanwhile, we also revealed that Foxc1 could promote bone regeneration induced by intermittent PTH treatment in vivo. Taken together, this study revealed the role and mechanism of Foxc1 on in vitro osteogenic differentiation and in vivo bone regeneration in response of intermittent PTH treatment.

Keywords: parathyroid hormone, Foxc1, Runx2, osteogenic differentiation, bone regeneration
INTRODUCTION

Parathyroid hormone (PTH) is released from the parathyroid gland responding to low serum calcium values and has significant impacts on bone metabolism (Delgado-Calle et al., 2017). As a major regulator of skeletal remodeling, PTH mediates both anabolic and catabolic processes of bone. PTH or its biological N-terminal fragment PTH (1–34) has been used as a therapy for osteoporosis for decades (Esen et al., 2015). Clinical researches indicated that intermittent PTH (1–34) administration could improve bone mass and decrease the risk of fracture in osteoporosis sufferers (Gardinier et al., 2015). Even though the impacts of intermittent PTH treatment on bone have been well reported, the targets and the underlying mechanisms responsible for bone formation induced by intermittent PTH have not been fully elucidated yet.

Meanwhile, the regulation of osteogenesis usually involves the collaborative activities of several signaling proteins and transcription factors (Hopkins et al., 2016b). Foxc1, which belongs to the transcription factors family named as Forkhead box or FOX genes, has an essential impact on regulation of intramembranous and endochondral ossification in normal development and bone formation (Mya et al., 2018a). Foxc1 null embryos displayed bony fusion of maxilla and mandible, accompanied by defects in maxilla, mandible, and agenesis of the temporomandibular joint (Inman et al., 2013). Foxc1 knockout mice showed severe defect in vertebrae, axial skeleton, and skull. Notably, their calvarium, consisted of the parietal, frontal, and intraparietal bones, were completely absent (Motojima et al., 2016). Mesenchymal progenitor cells from Foxc1 mutant mice were unable to differentiate into chondrocytes and osteoblast cells. Meanwhile, knockdown of Foxc1 levels by siRNA in C2C12 cells inhibited the process of osteogenesis (Hopkins et al., 2016b). What is more, in our previous studies, we also found that Foxc1 expression gradually increased during osteogenesis in human amniotic epithelial cells, amniotic fluid derived mesenchymal stem cells, and bone marrow mesenchymal stem cells (Si et al., 2015).

Notably, numbers of molecules had been proved to be important in response of PTH on osteogenesis, including IGF, NFATc1, BMP4, Msx2, and so on (Nagel et al., 2015; Khan et al., 2016), and they were also proved to be the downstream molecules of Foxc1 during osteogenesis (Wang et al., 2016b; Hariri et al., 2018). In the meantime, we also found that the expression level of Foxc1 was upregulated during osteogenic induction by intermittent PTH treatment. These findings implied a possible relationship between Foxc1 and PTH in osteogenic differentiation. As yet, the specific function of Foxc1 in PTH-induced osteogenesis is still unknown.

Herein, we determined the effect of Foxc1 on in vitro osteogenic differentiation and in vivo bone regeneration under intermittent PTH treatment, and further explored its possible targets for better understanding of the molecular mechanism.

MATERIALS AND METHODS

Cell Culture

Rat bone mesenchymal stem cells (rBMSCs) were isolated from rat tibia and femurs, and cultured as previously described (Lennon and Caplan, 2006). Cells were cultured in Dulbecco’s modified Eagle’s essential medium (DMEM, Gibco, USA) with 10% fetal bovine serum (FBS, Gibco, USA), 100 U/ml penicillin G, and 100 μg/ml streptomycin, in a humidified incubator at 37°C with 5% CO₂. Mouse pre-osteoblastic MC3T3-E1 cells (ATCC, USA) were cultured in α-Minimum Essential Medium (α-MEM, HyClone, USA) with 10% FBS (HyClone, USA) and 1% penicillin G and streptomycin. To simulate intermittent exposure of PTH, 10 nM PTH (1–34) treatment was conducted for 6 h, followed by basic medium treatment in the next 42 h following a 48-h cycle (Sun et al., 2009).

PTH1R Silencing

PTH1R small interfering RNAs (siRNA) were synthesized by Genomeditech (China) (sequences in Table 1). PTH1R siRNA (50 nM) was transfected into rBMSCs cells by Lipofectamine2000 according to the manufacturer’s protocol (Invitrogen, USA). Knockdown efficiency was measured by qPCR and Western blot after 48 h.

Lentivirus (LV) and Adeno-Associated Virus (AAV) Preparation and Transfection

Lentiviruses for Foxc1 gene overexpression, and Foxc1 silencing were constructed. Briefly, the full-length mouse Foxc1 gene, short hairpin RNAs targeting Foxc1 were encoded into different vectors obtained from Genomeditech (China) (Sequencing results in Supplementary Data 1, 2). The vectors and their packaging plasmids were transfected at the same time into 293T cells by Lipofectamine2000 (Invitrogen, USA). After changing the medium 8 h after transfection, the supernatant was collected, filtered, and went through ultracentrifugation 40 h later. 293T cells were then transduced with serially diluted lentivirus. Four days after that, recombinant high-titer lentiviral vectors with Foxc1 and shFoxc1 were collected.

Cells were seeded in 6-well plates (1 × 10⁵ cells/well) and transduced with the control lentiviruses (LV-vector or Lv-scramble), Foxc1-overexpressing lentivirus (LV-Foxc1) and short hairpin Foxc1 lentivirus (LV-shFoxc1–1, LV-shFoxc1–2, LV-shFoxc1–3) (primer sequences of interfering plasmids in Table 3). A 10-µg/ml polybrene was used for improvement of transduction efficiency.

TABLE 1 | siRNA sequences of PTH1R.

| Primer   | Sequence                  |
|----------|---------------------------|
| PTH1R-F  | GGCAGAUCGACAGCAUJATT      |
| PTH1R-R  | UAAUGCAUCUGGAGAUCCCTT     |
Meanwhile, Foxc1-ShRNA plasmid (primer sequences in Table 4 and sequencing results in Supplementary Data 3) was introduced into 293 adeno-associated virus (AAV) cells to generate viruses (AAV-shFoxc1) for rat Foxc1 knockdown, and the control virus was packaged with the plasmid pAAV-ZsGreen-ShRNA (AAV-scramble). rBMSCs were transduced with AAV at a multiplicity of infection (MOI) of 50 and cultured for 2 days (Chen et al., 2018). For transplantation in vivo, the cells were allowed to recover for 24 h before harvesting.

### RT-qPCR

Total cellular RNA was isolated by a standard protocol with easy RNA isolation kit (Takara, Japan). RT-qPCR was carried out with the following cycles: stage 1: 95°C for 30 s; stage 2: 95°C for 5 s, 60°C for 30 s for 40 cycles. Sequences of the primers are shown in Tables 5 and 6.

### Western Blot

Protein was extracted with RIPA Lysis Buffer at 4°C. After quantification, an equal volume of cell lysate was loaded and separated on a 10% SDS-PAGE gel, and then transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, USA).

### Alkaline Phosphatase Staining and Quantitative Analysis

For alkaline phosphatase (ALP) staining, cells were soaked in BCIP/NBT solution (Beyotime, China) in darkness, and purple-stained areas were considered positive. For level of ALP activity, the detection was performed following the manufacturer’s instructions (Beyotime, China). Briefly, 400-µl lysis buffer was added to the samples followed by a 4-h incubation at 37°C and a 30-min vibration at room temperature. After that, samples were mixed with p-Nitrophenyl phosphate (p-NPP) and substrate buffer, followed by a 10-min vibration and a 15-min incubation at 37°C. The enzyme activity was measured at 405 nm (BioTek, USA). The protein amount was obtained with the Bradford method in aliquots with the protein assay kit (Bio-Rad, USA), and absorbance was measured at 630 nm with protein concentration was being calculated according to a series of BSA standards (Sigma, USA). ALP activity was determined as absorbance at 405 nm per mg of total cellular proteins.

### Alizarin Red S Staining and Calcium Deposition Assay

After fixing and an additional washing, cells were soaked in 40 mM Alizarin red S (ARS) solution (pH 8.8) at 37°C for 30 min. On the other hand, the calcium deposition analysis was carried out following the manufacturer’s instructions (Sigma, USA). Briefly, a standard curve was prepared by Calcium Standard into a series of wells to give 0, 0.4, 0.8, 1.2, 1.6, 2.0 µg calcium per well. A 90-µl chromogenic reagent and a 60-µl calcium assay buffer were then added to each well containing standards, samples, or controls and mix gently followed by a 5-min incubation at room temperature. After that, the absorbance was measured at 595 nm, and the calcium concentration was being calculated according to a series of BSA standards (Sigma, USA).

### TABLE 2 | Primer sequences of expression plasmid.

| Primer | Sequence (5’ to 3’) |
|--------|---------------------|
| Foxc1-F (EcoRI) | CCGGAATTCATGGGCGGGGCAATTC-3’ |
| Foxc1-R (BamHI) | CCGGAATTCATGGGCGGGGCAATTC-3’ |

### TABLE 3 | Target sequences of interfering plasmids of mouse Foxc1.

| Plasmid | Target Sequence (5’ to 3’) |
|---------|-----------------------------|
| shRNA1  | GCACAACCTCTGCTTTATAGA-3’ |
| shRNA2  | GCAGGGATGTTGACATGCT-3’ |
| shRNA3  | GAATGGGGAATAGTAGCTGA-3’ |

### TABLE 4 | Target sequences of interfering plasmids of rat Foxc1.

| Plasmid | Target Sequence (5’ to 3’) |
|---------|-----------------------------|
| shRNA   | GAATGGGGAATAGTAGCTGA-3’ |

### TABLE 5 | Real-Time PCR primer sequences for target genes (rBMSCs).

| Gene(rat) | Sequence |
|-----------|----------|
| GAPDH     | Forward: 5’-CACCCCGCGGTGAGCACCTTC-3’ | Reverse: 5’-CCCTATCCGCCCATACACC-3’ |
| Foxc1     | Forward: 5’-GCTGCTGCTCTCTATACCCA-3’ | Reverse: 5’-GCTGCTGCTCTCTATACCCA-3’ |
| Pth1r     | Forward: 5’-AGGAGGATGTTGACATGCT-3’ |Reverse: 5’-CCCTATCCGCCCATACACC-3’ |
| Runx2     | Forward: 5’-GCCAAACATGGGCGGGATAC-3’ |Reverse: 5’-GCTGCTGCTCTCTATACCCA-3’ |
| OSX       | Forward: 5’-AGGAGGATGTTGACATGCT-3’ |Reverse: 5’-GCTGCTGCTCTCTATACCCA-3’ |
| OCN       | Forward: 5’-AGGAGGATGTTGACATGCT-3’ |Reverse: 5’-GCTGCTGCTCTCTATACCCA-3’ |

### TABLE 6 | Real-Time PCR primer sequences for target genes (MC3T3-E1).

| Gene(mice) | Sequence |
|------------|----------|
| GAPDH      | Forward: 5’-GACCTGAACAGGCAATCCCT-3’ | Reverse: 5’-TCCACCGCTTGTGCTTGT-3’ |
| Foxc1      | Forward: 5’-GACCTGAACAGGCAATCCCT-3’ | Reverse: 5’-GCTGCTGCTCTCTATACCCA-3’ |
| Runx2      | Forward: 5’-GCTGCTGCTCTCTATACCCA-3’ |Reverse: 5’-GCTGCTGCTCTCTATACCCA-3’ |
| OSX        | Forward: 5’-AGGAGGATGTTGACATGCT-3’ |Reverse: 5’-GCTGCTGCTCTCTATACCCA-3’ |
| OCN        | Forward: 5’-AGGAGGATGTTGACATGCT-3’ |Reverse: 5’-GCTGCTGCTCTCTATACCCA-3’ |

After blocking with 5% nonfat milk in PBS, the membrane was incubated with primary antibodies at 4°C overnight (anti-Foxc1 (1/1000; CST, USA), anti-Runtx2 (1/2000; Abcam, USA), anti-Osx (1/800; Abcam, USA), anti-Ocn (1/1000; Abcam, USA), and anti-GAPDH (1/2000; CST, USA). The membrane was washed with Tris-buffered saline plus 0.1% Tween 20 (TBST), and incubated with fluorescent secondary antibodies (anti-rabbit IgG and anti-rat IgG, 1/10000; CST, USA). The blot was scanned by Odyssey Infrared Imaging System (USA).
calcium sample amount (in µg) obtained from standard curve. Sv is the sample volume (µl) added into the sample well.

**Cell Proliferation Assay**

Cells were seeded into 96-well plates at the density of around 3,000 cells per well counted with cell counters under an inverted phase contrast microscope (Leica, Germany). After adherence, the cells were treated with 10-µl CCK-8 reagent (Dojindo Laboratories, Japan) for 2 h every day from 1st day to 7th day. The absorbance was detected at 405 nm.

**Immunofluorescence**

Cells were fixed in 4% paraformaldehyde (PFA) for 15 min and then washed with PBS. After incubation in a 5% bovine serum albumin (BSA, Sigma, USA) containing 3% Triton X-100 for 1 h, cells were then incubated with the following primary antibodies dissolved in 5% BSA at 4°C overnight: anti-Foxc1 (1/200; CST, USA), anti-Runx2 (1/500; Abcam, USA). On the next day, cells were incubated with the following secondary antibodies for an hour: Alex Fluor 594 and Alex Fluor 488 (1/1000; Abcam). DAPI solution (Invitrogen, USA) was used for nuclear staining. Images were taken with a Canon fluorescence microscope (Japan).

**Luciferase Assay**

Cells were seeded into a 24-well plate (at a density of around 4 × 10^4 cells/well) 24 h before transfection. On the next day, cells were transduced with 50 ng of mouse Runx2 reporter construct (Genomeditech, China), along with 250 ng of overexpression Foxc1 vector or control vector. Luciferase-reporter assays were conducted following the manufacturer’s instructions (Promega, USA).

**Chromatin Immunoprecipitation**

Chromatin immunoprecipitation (ChIP) assay was conducted following the manufacturer’s protocol (Millipore, USA). Cells were cross-linked with formaldehyde and incubated with sodium citrate to terminate the cross-linking reaction. Chromatin was sonicated with a sonication buffer followed by an incubated with 1 µg anti-Foxc1 or rabbit IgG overnight. Purification of the DNA fragments were carried out with Phenol-Chloroform extraction. After that, RT-qPCR were conducted for sample analysis. The primers are listed in Table 7.

**Animals and Experiment Design In Vivo**

Three-month-old female Sprague Dawley rats with an average weight of 232 ± 7 g were enrolled. The experiment was reviewed and approved by the Ethics Committees of the Shanghai 9th People’s Hospital, School of Medicine, SJTU. A cranial defect model was established to determine the role of Foxc1 in bone regeneration induced by intermittent PTH treatment in vivo. After anesthetization of 10% chloral hydrate by intraperitoneal injection (4 ml per kg of body weight), a 1.0-cm sagittal cut was made through the skin on the scalp, and the periosteum was carefully elevated. When the skull was exposed, a 5-mm diameter bone defect was made in the midline by a 5-mm diameter round bur and cooled with continuous saline buffer irrigation. Scaffolds seeded with cells were then implanted into the defects followed by incision closure.

Thirty-two rats were randomly allocated into four groups: Group A, defect+β-TCP scaffolds+ BMSCs+ PBS (n = 8); Group B, defect+ β-TCP scaffolds+ BMSCs+ intermittent PTH treatment (n = 8); Group C, defect+ β-TCP scaffolds+ intermittent PTH treatment+ AAV-scramble BMSCs (n = 8); and Group D, defect+ β-TCP scaffolds+ AAV-shFoxc1 BMSCs + intermittent PTH treatment (n = 8). β-TCP scaffolds were from Shanghai Institute of Ceramics, Chinese Academy of Sciences. The scaffold diameter was 5 mm, and its thickness was 1.5 mm, while the pore size was around 350 to 500 µm, and the average porosity being about 80%. BMSCs of different groups were washed from the culture dishes. After centrifugation, BMSCs were resuspended in serum-free DMEM medium. Next, BMSCs were seeded at a concentration of 1.0 × 10^5 cells per ml on to the scaffolds and incubated for 4 h before implantation (Fan et al., 2016). Intermittent PTH treatment was achieved by intraperitoneally injected with rhPTH1–34 (80 µg/kg) (Kang et al., 2014) or PBS once a day for 8 weeks. Eight weeks later, micro-CT examination and bone parameter analysis were performed after fixation.

**Micro-Computed Tomography Scans**

The samples were collected and fixed in 4% PFA for micro-computed tomography (µ-CT) examination (GE Healthcare Life Sciences, USA). Thickness of the slices was 0.01 mm. Three-dimensional reconstructions were performed, and parameters regarding bone mineral density were analyzed (GE Healthcare Life Sciences, USA).

**H&E Staining**

The samples were collected and fixed in 4% PFA and further demineralized in 0.5 M ethylenediaminetetraacetic acid (EDTA). After that, the samples were embedded and cut with slices of 5-mm thick for regular H&E staining, and images were obtained with an upright metallurgical microscope (Nikon, Japan).

**Statistical Analysis**

The experiments were all carried out for at least three times. All data were displayed as mean ± SD, and the statistical analysis was carried out by SPSS 20.0 software (SPSS Inc., USA). Differences between two groups were evaluated by two-tailed Student’s t test. ANOVA was used to determine significance between multiple groups. Levene’s test was firstly used for testing the assumption that the group variances are homogenous. When the homogeneity of variances assumption was met, the overall

---

**Table 7**

| Primer     | Sequence (5’ to 3’) | Product (bp) |
|------------|---------------------|--------------|
| Runx2-1-F  | TTGTAAGACGCGCCACGTAA | 145          |
| Runx2-1-R  | AGCCTGCGTTGAGAACCTCT |              |
| Runx2-2-F  | CCTTACGAGGAGTGGGCTCT | 103          |
| Runx2-2-R  | TAAGGCCCTGCGGACATCAC |              |
| Runx2-3-F  | AGGCAGTCCACCTTTACCTG | 74           |
| Runx2-3-R  | CAGGCACATTACTGCGAGAGACAGA |        |
comparison was performed using the F test and Tukey test was utilized for the pairwise comparisons. When the homogeneity of variances assumption was not met, Welch’s test was used and Dunnett’s T3 test was utilized for the pairwise comparisons. P < 0.05 was considered statistically significant.

RESULTS

Expression Level of Foxc1 Induced by Intermittent PTH Treatment

To identify the effects of PTH-induced osteogenic differentiation on the expression level of Foxc1, rBMSCs were treated with intermittent PTH as indicated. The qPCR results indicated that mRNA expression level of Foxc1 increased gradually and PTH stimulated a significant increase to the maximal level on the 5th day (Figure 1A). Western blot exhibited consistent results with qPCR (Figures 1B, C), revealing that expression level of Foxc1 was upregulated during osteogenic induction by intermittent PTH treatment.

Effect of PTH1R Silencing on the Expression of Foxc1 and PTH-Induced Osteogenic Differentiation

As parathyroid hormone 1 receptor (PTH1R) is the predominant receptor of PTH, the expression of PTH1R in rBMSCs was inhibited by RNAi-targeted silencing to further investigate the effect of PTH/PTH1R on Foxc1 expression level and on the role of osteogenic differentiation by PTH treatment. Forty-eight hours after transfection, the expression level of PTH1R in control group was relatively high, while that in si-PTH1R group expressed a remarkable decrease (Figures 1D, E). To determine the impacts of PTH1R silencing on Foxc1 expression during osteogenesis induced by intermittent PTH treatment, expression levels of Foxc1 were detected on the 3rd day. It turned out that the elevated Foxc1 expression level induced by intermittent PTH treatment was inhibited by PTH1R silencing, while rescued by PTH supplement after PTH1R silencing (Figures 1F, G). The results of ALP staining on the 7th day showed similar tendency with the expression of Foxc1, indicating the potential role of Foxc1 on osteogenic differentiation induced by intermittent PTH treatment (Figures 1H, I).

Effect of Foxc1 on Osteogenic Differentiation Induced by Intermittent PTH Treatment In Vitro

In order to evaluate whether Foxc1 takes a major part in PTH-induced osteogenesis, gain- and loss-of-function assays with Foxc1 overexpressing and Foxc1-knockdown cells were performed. qPCR results revealed that Lv-Foxc1 MC3T3-E1 cells showed a strong mRNA expression of Foxc1 (Figure 2A) and a correspondingly high protein production compared with Lv-vector MC3T3-E1 (Figures 2B, C), indicating that lentivirus was successfully transfected, and overexpression of Foxc1 in MC3T3-E1 cells was stably induced. Meanwhile, cell proliferation rate measured by CCK8 indicated that Lv-Foxc1 did not have significant impact on proliferation rate of MC3T3-E1 cells (Figure 2D). Compared with Lv-vector MC3T3-E1 cells, Runx2, and Osx mRNA expression levels were higher in Lv-Foxc1 MC3T3-E1 cells on the 1st day, 4th day, and 7th day after exposed to intermittent PTH treatment. The mRNA expression level of Ocn was significantly upregulated on the 4th day and 7th day (Figure 2E). In the meantime, overexpression of Foxc1 resulted in an increase in Runx2, Osx, and Ocn protein expression levels on the 1st day, 4th day, and 7th day (Figures 2F, G). ALP expression was well detected in Lv-Foxc1 MC3T3-E1 cells after 14 days of intermittent PTH treatment (Figure 2H), and the ALP activity increased by nearly three folds compared with Lv-vector MC3T3-E1 cells (Figure 2J). Similarly, Alizarin red S staining and calcium concentration assay both exhibited higher osteogenic potential in Lv-Foxc1 MC3T3-E1 cells (Figures 2I, K).

At the same time, three shRNAs were designed to knock down the expression of Foxc1, and the efficiency was analyzed at protein and mRNA levels. qPCR and western blot results indicated that LV-shFoxc1–2 and LV-shFoxc1–3 could downregulate Foxc1 expression, and the inhibition effect of LV-shFoxc1–3 was more obvious (Figures 3A–C). Expression levels of Runx2, Osx, and Ocn were significantly decreased after Foxc1 knocking down on the 4th day in the osteogenic differentiation process induced by intermittent PTH treatment (Figures 3D–F). ALP staining was performed 14 days after PTH-induced osteogenic differentiation. It turned out that LV-shFoxc1–3 inhibited ALP activity on the 14th day (Figure 3G), while quantitative measurements confirmed the above results (Figure 3I). In addition, LV-shFoxc1–3 MC3T3-E1 cells showed lighter alizarin red S staining and less calcium nodule formation on the 21st day (Figures 3H, J). So far, our gain- and loss-of-function experiment results demonstrated that Foxc1 can promote osteogenic differentiation induced by intermittent PTH treatment in vitro.

Role of Foxc1 in Regulating Runx2 Promoter Activity and Transcription

As the immunofluorescence analysis indicated the nuclear colocalization of Foxc1 with Runx2 (Figure 4A), we further performed a luciferase reporter assay for evaluation of Runx2 promoter activity in PTH-induced osteogenic differentiation to investigate the potential role of Foxc1 in modulating Runx2 gene promoter activity. We found that the promoter activity of Runx2 was significantly upregulated by Foxc1 overexpression (Figure 4B). These results indicated that Foxc1 could enhance the transcriptional activity of the Runx2 promoter.

Furthermore, in order to identify the underlying regulation mechanism of Foxc1 on Runx2 expression, the structure and function of mouse Runx2 gene promoter were examined. Bioinformatics analysis through the JASPAR database revealed three potential Foxc1-binding elements in mice Runx2 promoter region (Figure 4C). The binding
of Foxc1 to the promoter region of Runx2 was further detected through a chromatin immunoprecipitation assay using anti-Foxc1 as described. Chromatin immune complexes obtained from PTH-induced osteoinductive medium of MC3T3-E1 cells upon 3 days were analyzed by qPCR using Runx2 promoter gene specific primers for the Foxc1-binding region. As shown in Figure 4D, functional Region1 and Region2, located at 929 to −785 bp, and −447 to −345 bp relative to transcription initiation site, were responsive to the stimulation from Foxc1.

**FIGURE 1** | Expression of Foxc1 was increased by intermittent PTH treatment and PTH1R silencing inhibited the expression of Foxc1 and PTH-induced osteogenic differentiation. (A) mRNA expression level of Foxc1 at different time points induced by intermittent PTH treatment for 7 days in rBMSCs. (B, C) Protein expression level and quantitative analysis of Foxc1 at different time points by intermittent PTH treatment for 7 days in rBMSCs. (D, E) PTH1R mRNA and protein expression at 48 h after transfection in rBMSCs in control group (si-Ctrl) and PTH1R silencing group (si-PTH1R). (F, G) Foxc1 mRNA and protein expression on the 3rd day in control group (Ctrl), intermittent PTH treatment group (PTH), PTH1R silencing group (si-PTH1R) and PTH1R silencing group with intermittent PTH treatment (si-PTH1R+PTH). (H, I) ALP staining and its quantitative analysis on the 7th day in control group (Ctrl), Intermittent PTH treatment group (PTH), PTH1R silencing group (si-PTH1R) and PTH1R silencing group with intermittent PTH treatment (si-PTH1R+PTH). Scale bar = 50 μm. *p < 0.05, **p < 0.01, ***p < 0.001.
Effect of Foxc1 in the Process of Bone Regeneration Induced by Intermittent PTH Treatment In Vivo

To evaluate whether PTH modulates Foxc1 function in vivo, we utilized a rat cranial defect model and implanted β-TCP scaffolds loaded with BMSCs. After 8 weeks of implantation, 3D reconstruction images of µ-CT for the defect area (Figure 5A) showed little mineralization in PBS+BMSCs control group (group A) and only a slight amount of mineralization in PTH+ AAV-shFoxc1 BMSCs group (group D). On the other hand, newly formed bone was detected at the edge of the defect area in both PTH+ BMSCs group (group B) and PTH+ AAV-scramble BMSCs group (group C). The diameters of the defect area decreased more or less in all the groups. New bone formation

FIGURE 2 | Foxc1 overexpression stimulated osteogenic differentiation induced by intermittent PTH treatment in vitro. (A) mRNA expression level of Foxc1 in Lv-vector and Lv-Foxc1 MC3T3-E1 cells at 48 h after transfection. (B, C) Protein expression level and quantitative analysis of Foxc1 at 48 h after transfection. (D) Cell proliferation rate in Lv-vector and Lv-Foxc1 MC3T3-E1 cells. (E) mRNA expression levels of the osteogenic markers, Runx2, Osx and Ocn on the 1st day, 4th day, and 7th day after exposed to intermittent PTH treatment. (F, G) Protein expression level and quantitative analysis of the osteogenic markers, Runx2, Osx, and Ocn on the 1st day, 4th day, and 7th day after exposed to intermittent PTH treatment. (H, J) ALP staining and activity in Lv-Foxc1 and Lv-vector MC3T3-E1 cells after 2 weeks of intermittent PTH treatment. (I, K) Alizarin red S staining and calcium concentration in Lv-Foxc1 and Lv-vector MC3T3-E1 cells after 3 weeks of intermittent PTH treatment. (I, K). Scale bar = 50 μm. \(^* p < 0.05, \^{**} p < 0.01, \^{***} p < 0.001.\)
in groups B and C was more obvious compared with groups A and D, and that in group B was the most prominent one. Bone volume density (BV/TV) analysis indicated that bone volume of group B was significantly higher than that of groups A and D, while no difference was detected significantly within groups C and B. Meanwhile, bone volume of group C was also higher than that of groups A and D (Figure 5B). Trabecular number of group B was greatly upregulated compared with that of groups A and D, and so was that of group C, while no difference was detected significantly within groups B and C neither (Figure 5C). The trabecular thickness (Tb.Th) exhibited same tendency with the number of trabecular (Figure 5D), and results of trabecular bone spacing (Tb.Sp) also displayed similar patterns, indicating more newly formed bone in groups B and C than in groups A and D (Figure 5E).

Consistent with the μ-CT results, instead of new bone, more fibrous connective tissues were detected in the defect area of groups A and D. In contrast, more newly formed bone and osteoid appeared in the bone stump in groups B and C, particularly in group B (Figures 5F–M). Meanwhile, the mRNA expression levels of Foxc1, Runx2, and Ocn in groups B and C were also greatly upregulated compared with those in groups A and D (Figure 5N). These results indicated that β-TCP scaffolds loaded with BMSCs and induced by intermittent PTH treatment at the same time have the best bone regeneration potential among all the groups, while knocking down of Foxc1 could inhibit the bone regeneration process induced by intermittent PTH treatment, suggesting the vital role of Foxc1 in bone regeneration induced by intermittent PTH treatment in vivo.
DISCUSSION

Intermittent PTH administration has been used for clinical bone stimulation in osteoporosis patients for decades (Vrahmas et al., 2016). As a common receptor of PTH, PTH1R is in charge of various cellular processes and generally expressed in cells and tissues. In the skeleton, the expression of PTH1R could be detected in osteocytes and osteoblasts, with higher levels in the former cells (Delgado-Calle et al., 2017). However, the mechanism of which PTH/PTH1R stimulates skeletal formation still needs exploration. Herein, we revealed that elevated expression of Foxc1 and upregulated ALP activity induced by intermittent PTH treatment was inhibited by PTH1R silencing, while rescued by PTH supplement, indicating the potential role of Foxc1 on osteogenic differentiation in response of intermittent PTH treatment targeting PTH1R. Previous researches have shown that Foxc1 is an important regulator in both endochondral ossification and intramembranous ossification. Foxc1-mutant mice die during embryonic period due to similar defects in skeleton, oculus, and cardiovascular system, along with hydrocephalus and hypoplasia of cerebellum (Seo and Kume, 2006). It is worth noting that the most severe skeletal mutations of Foxc1 knockout mice is calvarium deficiency (Rice et al., 2003), and thus we utilized a rat cranial defect model in this study to evaluate whether PTH modulates Foxc1 function in vivo. Meanwhile, mutations in Foxc1 in humans are often related with autosomal dominant diseases as the Axenfeld-Rieger and Dandy Walker syndromes. Malformations of the Axenfeld-Rieger syndrome includes tooth abnormalities, maxillary hypoplasia, dysplasia of the anterior eye segment, and defects of the cardiac flow tract (Seifi and Walter, 2018). As the most common congenital disorders of cerebellum, affected individuals of Dandy-Walker syndrome were often detected with duplications or deletions within the Foxc1 gene (Haldipur et al., 2017). What is more, Foxc1 is profoundly expressed in pre-osteogenic stem cells and is crucial for the formation of cell niche (Omatsu et al., 2014). Also, in self-renewing stem cells, Foxc1 activates the BMP and Nfatc1 pathways and reinforces the quiescence (Wang et al., 2016b). Notably, recent studies showed that ossification centers of long bones were lessened in Foxc1 knockout mice and that Foxc1 could regulate the expression of PTHrP, indicating functional links between Foxc1- and PTH-related osteogenic differentiation (Hopkins et al., 2016a). As the effect of Foxc1 on osteogenesis in response of intermittent PTH has not been verified yet, we used intermittent PTH in this study to induce osteogenic differentiation. After confirming the upregulated expression level of Foxc1, we then revealed that Foxc1 positively regulate osteogenic differentiation in response of intermittent PTH treatment targeting PTH1R.

Furthermore, as a transcription factor, it has been reported that Foxc1 could directly bind on the enhancer region of Bmp and inhibit phosphorylation of Smad1/5/8, playing an essential role in bone formation.
part in Bmp-dependent Msx2 activation (Sun et al., 2013b). Foxc1 was also reported to be directly regulated by the Yap-Tead complex, suggesting its essential role in diversification and development of central nerve crests (Wang et al., 2016a). Thus, more target genes of Foxc1 should be identified in bone-forming cells for better understanding of osteogenesis. Notably, we found that the expression level of Runx2, the key transcription factor for osteogenesis, changed with Foxc1 and immunofluorescence analysis also indicated the nuclear co-localization of Foxc1 with Runx2. In our research, we revealed that the upregulation of

![Figure 5](image-url)

**FIGURE 5 |** Foxc1 stimulates osteogenic differentiation induced by intermittent PTH treatment *vivo*. (A) Three-dimensional reconstruction images of the defect sites by micro-CT in different groups at 8 weeks. (B–E) BV percentage (B), trabecular number (C), trabecular thickness (D), and the number of trabecular (E) in different groups were quantified. (F–M) H&E staining of the defect sites in different groups at 8 weeks. (N) mRNA expression levels of Foxc1, Runx2, and Ocn in different groups at 8 weeks. Scale bar = 5 mm in (A). Scale bar = 10 μm in (F–I). Scale bar = 25 μm in (J–M). (F–M) are local amplification of boxed area in (F–I), respectively. Arrow indicates new bone formation. *p < 0.05, **p < 0.01, ***p < 0.001.
Foxc1 expression appeared at an early stage in osteogenic differentiation \textit{in vitro}. Researchers also found that Foxc1 was detected in ectoderm and craniofacial mesenchyme of mouse embryos at E8.5 and in the first zygomatic arch at E9.5, while Runx2 was detected in the osteogenic precursor matrix at E10.5, suggesting the potential regulating effect of Foxc1 on Runx2 in osteogenic differentiation (Sun et al., 2013a; Mya et al., 2018b). Such hypothesis was confirmed by luciferase reporter assay, and it turned out that Foxc1 could enhance the transcriptional activity of Runx2.

After that, we analyzed the structure and function of mouse Runx2 gene promoter in order to elucidate the underlying regulation mechanism of Foxc1 on Runx2 expression. It was reported that Runx2 had two isoforms with different N-terminals and was transcribed from the distal and proximal promoters, named as P1 and P2. The P2 promoter maintains basal expression level of Runx2 in thymus, cartilage, periosteam, and cranial suture (Ng et al., 2007), while the P1 or the “bone-related” promoter is widely involved in bone development and plays a predominant role in hypertrophic differentiation of chondrocytes and osteoblasts (Ducy et al., 1997). For osteoblastic-related cells, it is reported that Runx2 was mostly transcribed from the P1 promoter. Further studies demonstrated that Sp1/Elk1, Tcf7/Ctnnb1, Fosb/Jund, Msx2, Dlx5, and Hoxa10 bind to the P1 promoter of Runx2 in the proximal 700-bp region and thus regulate its transcriptional activity \textit{in vitro} (Komori, 2017; Komori, 2018). Based on the former data and bioinformatics analysis through the JASPAR database, we herein used a luciferase reporter assay and a ChIP assay to verify the regulation effect of Foxc1 on Runx2. Our results revealed that Foxc1 not only enhanced the promoter activity of Runx2, but also bound to the two promoter regions of Runx2, Region1, and Region2, with Region2 located in the P1 promoter region. Therefore, it was confirmed that Foxc1 could bind to the promoter region and directly regulate Runx2.

It is worth noting that Berry \textit{et al.} reported that Foxc1 is a short-lived protein with its protein levels and activity regulated by post-translational modifications, and serine 272 is an important residue in maintaining proper stability of Foxc1 (Berry \textit{et al.}, 2006). Interestingly, Ito \textit{et al.} pointed out that inhibiting phosphorylation of serine 272 residue impairs the stability, but increases the transcriptional activity of Foxc1 (Ito \textit{et al.}, 2014). Meanwhile, Hayashi \textit{et al.} found that Foxc1 have 10 potential phosphorylation sites for ERK but there is no potential ERK1/2 phosphorylation site in the DNA-binding domains (Hayashi and Kume, 2008). These indicated that the stability, transcriptional activity, and protein level of Foxc1 are regulated by various complicated factors, and further research should be carried out for obtaining more information.

In conclusion, as was shown in Figure 6, our study revealed that the expression of Foxc1 was elevated in intermittent PTH treatment and Foxc1 could promote \textit{in vitro} osteogenic differentiation and \textit{in vivo} bone regeneration induced by intermittent PTH. Further exploration of the molecular regulatory mechanism revealed that Foxc1 could bind to the P1 promoter of Runx2 directly, which played an indispensable role in osteogenesis and bone mineralization. These results help us understand the role of Foxc1 in osteogenesis in response of intermittent PTH and may provide a possible molecular target for bone regeneration.

**DATA AVAILABILITY STATEMENT**

The datasets generated for this study are available on request to the corresponding authors.
ETHICS STATEMENT

The animal study was reviewed and approved by the Animal Ethical Committee at the Ninth People’s Hospital affiliated to Shanghai Jiaotong University, School of Medicine.

AUTHOR CONTRIBUTIONS

The conception and design of the study: GS and JS. Project administration, investigation, and drafting the article: NO and HL. Data curation and formal analysis: NO, MW, and HS. All authors read and approved the final manuscript.

REFERENCES

Ben-Awadh, A. N., Delgado-Calle, J., Tu, X., Kuhlenschmidt, K., Allen, M. R., Plotkin, L. I., et al. (2014). Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes. Endocrinology 155, 2797–2809. doi: 10.1210/en.2014-1046

Berry, F. B., Mirzayans, F., and Walter, M. A. (2006). Regulation of FOXC1 stability and transcriptional activity by an epidermal growth factor-activated mitogen-activated protein kinase signaling cascade. J. Biol. Chem. 281, 10098–10104. doi: 10.1074/jbc.M513629200

Chen, B., Chen, X., Liu, C., Li, J., Liu, F., and Huang, Y. (2018). Co-expression of Akt1 and Wnt11 promotes the proliferation and cardiac differentiation of mesenchymal stem cells and attenuates hypoxia/reoxygenation-induced cardiomyocyte apoptosis. Biomed. Pharmacother. Biomed. Pharmacother. 108, 508–514. doi: 10.1016/j.biopharm.2018.09.047

Delgado-Calle, J., Tu, X., Pacheco-Costa, R., Mcandrews, K., Edwards, R., Pellegrini, G. G., et al. (2017). Control of Bone Anabolism in Response to Mechanical Loading andPTH by Distinct Mechanisms Downstream of the PTH Receptor. J. Bone Miner. Res. 32, 522–535. doi: 10.1002/jbmr.3011

Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., and Karsenty, G. (1997). Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89, 747–754. doi: 10.1016/S0092-8674(00)80257-3

Esen, E., Lee, S.-Y., Wice, B. M., and Long, F. (2015). PTH Promotes Bone Anabolism by Stimulating Aerobic Glycolysis via IGFl Signaling. J. Bone Miner. Res. 30, 1959–1968. doi: 10.1002/jbmr.2556

Fan, D., Liu, S., Jiang, S., Li, Z., Mo, X., Ruan, H., et al. (2016). The use of SHP-2 gene transduced bone marrow mesenchymal stem cells to promote osteogenic differentiation and bone defect repair in rat. J. Biomed. Mater. Res. Part A 104, 1871–1881. doi: 10.1002/jbma.35718

Gardiner, J. D., Mohamed, F., and Kohn, D. H. (2015). PTH Signaling During Exercise Contributes to Bone Adaptation. J. Bone Miner. Res. 30, 1053–1063. doi: 10.1002/jbmr.2432

Haldipur, P., Dang, D., Aldinger, K. A., Janson, O. K., Guimiot, F., Adle-Biasette, H., et al. (2017). Phenotypic outcomes in Mouse and Human FoxC1 dependent Dandy-Walker cerebellar malformation suggest shared mechanisms. eLife 6, e20898. doi: 10.7554/eLife.20898

Hartr, H., Kurbani, M., Al-Haddad, C., Fahed, A. C., Poladian, S., Khalil, A., et al. (2018). Degenerated hair follicle cells and partial loss of sebaceous and eccrine glands in a familial case of axenfield-rieger syndrome: An emerging role for the FOXC1/NFATC1 genetic axis. J. Dermatol. Sci. 92, 237–244. doi: 10.1016/j.jdermsci.2018.11.003

Hayashi, H., and Kume, T. (2008). Foxc transcription factors directly regulate Dll4 and Hey2 expression by interacting with the VEGF–Notch signaling pathways in endothelial cells. Plos One 3, e2401. doi: 10.1371/journal.pone.0002401

Hopkins, A., Mirzayans, F., and Berry, F. (2016a). Foxc1 Expression in Early Osteogenic Differentiation Is Regulated by BMP4-SMAD Activity. J. Cell Biochem. 117, 1707–1717. doi: 10.1002/jcb.25464

Holmén, A., Purcell, P., Kume, T., and Trainor, P. A. (2013). Interaction between Foxc1 and FgB8 during mammalian jaw patterning and in the pathogenesis of synacthyia. PLoS Genet. 9, e1003949. doi: 10.1371/journal.pgen.1003949

Ito, Y. A., Goping, I. S., Berry, F., and Walter, M. A. (2014). Dysfunction of the stress-responsive FOXC1 transcription factor contributes to the earlier-onset glaucoma observed in Axenfeld-Rieger syndrome patients. Cell Death Dis. 5, e1069. doi: 10.1038/cddis.2014.8

Kang, Y., Ren, L., and Yang, Y. (2014). Engineering vascularized bone grafts by integrating a biomimetic periosteum and beta-TCP scaffold. ACS Appl. Mater. Interf. 6, 9622–9633. doi: 10.1021/am502056q

Khan, M. P., Khan, K., Yadav, P. S., Singh, A. K., Nag, A., Prasahar, P., et al. (2016). BMP signaling is required for adult skeletal homeostasis and mediates bone anabolic action of parathyroid hormone. Bone 92, 132–144. doi: 10.1016/j.bone.2016.08.018

Komori, T. (2017). Roles of Runx2 in Skeletal Development. Adv. Exp. Med. Biol. 962, 83–93. doi: 10.1007/978-981-10-3233-2_6

Komori, T. (2018). Runx2, an inducer of osteoblast and chondrocyte differentiation. Histochem. Cell Biol. 149, 313–323. doi: 10.1007/s00418-018-1640-6

Lennon, D. P., and Caplan, A. I. (2006). Isolation of rat marrow-derived mesenchymal stem cells. Exp. Hematol. 34, 1606–1607. doi: 10.1016/j.exphem.2006.07.015

Motojima, M., Tanimoto, S., Ohtsuka, M., Matsusaka, T., Kume, T., and Abe, K. (2016). Characterization of Kidney and Skeleton Phenotypes of Mice Double Heterozygous for Foxc1 and Foxc2. Cells Tissues Organs 201, 380–389. doi: 10.1159/000445027

Mya, N., Furutera, T., Okuhara, S., Kume, T., Takechi, M., and Iseki, S. (2018a). Transcription factor Foxc1 is involved in anterior part of cranial base formation. Congenit. Anomalies 58, 158–166. doi: 10.1111/cga.12268

Mya, N., Furutera, T., Okuhara, S., Kume, T., Takechi, M., and Iseki, S. (2018b). Transcription factor Foxc1 is involved in anterior part of cranial base formation. Congenit. Anomal. (Kyoto) 58, 158–166. doi: 10.1111/cga.12268

Nagel, S., Ehrentraut, S., Meyer, C., Kaufmann, M., Drexler, H. G., and Macleod, R. A. (2015). Repressed BMP signaling reactivates NKL homeobox gene MSX1 in a T-ALL subset. Leuk. Lymphoma 56, 480–491. doi: 10.3109/10428194.2014.924119

Ng, C. E., Osato, M., Tay, B. H., Venkatesh, B., and Ito, Y. (2007). cDNA cloning of Runx family genes from the pufferfish (Fugu rubripes). Gene 399, 162–173. doi: 10.1016/j.gene.2007.05.014

Omatzu, Y., Seike, M., Sugiyama, T., Kume, T., and Nagasawa, T. (2014). Foxc1 is a critical regulator of haematopoietic stem/progenitor cell niche formation. Nature 508, 536–540. doi: 10.1038/nature13071

Rice, R., Rice, D. P., Olsen, B. R., and Thesleff, I. (2003). Progression of calvarial bone development requires Foxc1 regulation of Msx2 and Alx4. Dev. Biol. 262, 75–87. doi: 10.1016/S0012-1606(03)00355-5

FUNDING

This work was supported by National Science Foundation of China (81771036, 81600827, 81570947), and Shanghai international science and technology cooperation projects (17410710500).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.00592/full#supplementary-material
Seifi, M., and Walter, M. A. (2018). Axenfeld-Rieger syndrome. *Clin. Genet.* 93, 1123–1130. doi: 10.1111/cge.13148

Seo, S., and Kume, T. (2006). Forkhead transcription factors, Foxc1 and Foxc2, are required for the morphogenesis of the cardiac outflow tract. *Dev. Biol.* 296, 421–436. doi: 10.1016/j.ydbio.2006.06.012

Si, J., Dai, J., Zhang, J., Liu, S., Gu, J., Shi, J., et al. (2015). Comparative investigation of human amniotic epithelial cells and mesenchymal stem cells for application in bone tissue engineering. *Stem Cells Int.* 2015, 565732. doi: 10.1155/2015/565732

Sun, Z. F., Jiang, H., Ye, Z. Q., Jia, B., Zhang, X. L., and Zhang, K. Q. (2009). Expression of Rho GDalpha in rat osteoblasts intermittently exposed to parathyroid hormone in vitro and in vivo. *Acta Pharmacol. Sin.* 30, 1001–1007. doi: 10.1038/aps.2009.60

Sun, J., Ishii, M., Ting, M. C., and Maxson, R. (2013a). Foxc1 controls the growth of the murine frontal bone rudiment by direct regulation of a Bmp response threshold of Msx2. *Dev. (Cambridge England)* 140, 1034–1044. doi: 10.1242/dev.085225

Sun, J., Ishii, M., Ting, M. C., and Maxson, R. (2013b). Foxc1 controls the growth of the murine frontal bone rudiment by direct regulation of a Bmp response threshold of Msx2. *Development* 140, 1034–1044. doi: 10.1242/dev.085225

Vrahnas, C., Pearson, T. A., Brunt, A. R., Forwood, M. R., Bambery, K. R., Tobin, M. J., et al. (2016). Anabolic action of parathyroid hormone (PTH) does not compromise bone matrix mineral composition or maturation. *Bone* 93, 146–154. doi: 10.1016/j.bone.2016.09.022

Wang, L., Xiao, Y., Hsu, C. W., Martinez-Traverso, I. M., Zhang, M., Bai, Y., et al. (2016a). Yap and Taz play a crucial role in neural crest-derived craniofacial development. *Development* 143, 504–515. doi: 10.1242/dev.126920

Wang, L., Siegenthaler, J. A., Dowell, R. D., and Yi, R. (2016b). Foxc1 reinforces quiescence in self-renewing hair follicle stem cells. *Sci. (N.Y.)* 351, 613–617. doi: 10.1126/science.aad5440

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Ouyang, Li, Wang, Shen, Si and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.